T Cell

T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.

Adoptive T Cell Therapy Methodology

Adoptive T cell therapy is a type of immunotherapy that has the ability to target cancer cells through inherent mechanisms of the immune system.

T-Cell Metabolism, Immunodeficiency and Human Disease

Adoptive T Cell Therapy Applications

CAR-T Cell Toxicity and Safety Profiles

Glioma microenvironment emerges as key target for future therapies

The prognosis for glioma patients remains extremely poor despite aggressive multimodal standard therapy: maximal safe resection, radiotherapy, and temozolomide chemotherapy, with median survival rarely exceeding 15 to 18 months.

20 Aug 2026

Red blood cells inspire next-generation therapeutic nanocarriers

Red blood cells serve as the foundation for nanocarriers that show promise in a new study as effective and efficient vehicles for gene therapy, tumor targeting and other medical treatments.

19 Aug 2026

UC Irvine researchers develop framework to make CAR T-cell therapy safer

CAR T-cell therapy has transformed cancer care, offering new hope to patients with aggressive blood cancers who once had few treatment options.

18 Aug 2026

UVA researchers find how postoperative delirium may set the stage for dementia

UVA Health researchers have discovered how a form of delirium that often strikes older patients after surgery may set the stage for dementia – and identified a drug that could reverse the underlying brain changes.

18 Aug 2026

Study provides new insights into how IL-26 reshapes the tumor immune landscape

While cancer cells acquire malignant traits through epigenetic remodeling, it remains unclear how immune-derived inflammatory factors regulate the epigenetics of colorectal cancer cells.

18 Aug 2026

Engineered red blood cell vesicles improve gene therapy delivery

Red blood cells serve as the foundation for nanocarriers that show promise in a new study as effective and efficient vehicles for gene therapy, tumor targeting and other medical treatments.

17 Aug 2026

Engineered immune cells help eliminate severe bacterial infections effectively

Severe bacterial infections remain a major global health challenge because antibiotics alone often fail when the host immune system becomes dysfunctional.

17 Aug 2026

Polydatin reduces ulcerative colitis by regulating intestinal immune cells

Ulcerative colitis (UC) is a chronic inflammatory bowel disease in which recurrent intestinal inflammation can be difficult to control over the long term.

17 Aug 2026

Researchers identify genes that hinder CRISPR editing efficiency

Like a delivery driver navigating crowded city streets, a gene-therapy-toting lipid nanoparticle faces a gauntlet of potential detours on its journey toward a cell's nucleus.

13 Aug 2026

Personalized T-cell therapy eliminates advanced kidney tumor in teenager

Researchers and physicians at the Hopp Children's Cancer Center Heidelberg (KiTZ) and other leading cancer centers report an exceptional treatment success in an adolescent with an advanced, therapy-resistant kidney tumor.

12 Aug 2026

Genetic tool turns soft cancer cells into immune targets

Researchers at the USC Viterbi School of Engineering and Keck School of Medicine of USC have engineered a remarkable genetic tool that addresses one of the most persistent obstacles in cancer immunotherapy: the physical softness of tumors.

11 Aug 2026

New gene signature predicts immunotherapy success for bone marrow cancers

A team led by researchers from the German Cancer Research Center (DKFZ), the HI-STEM Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital (UKHD) has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and, in principle, fight cancer cells, but is often not sufficiently activated.

10 Aug 2026

Integrated nanomaterials offer new strategies for cancer immunotherapy

Immune checkpoint inhibitors, cancer vaccines and cellular therapies have reshaped oncology, yet most patients still do not achieve lasting benefit.

9 Aug 2026

D-serine promotes gastric cancer growth by suppressing tumor immunity

Researchers from Keio University have found that D-serine increases the growth of gastric cancer by creating an immunosuppressive and anti-inflammatory tumor microenvironment.

6 Aug 2026

Risk-adapted frameworks reshape pediatric neuroblastoma care

Neuroblastoma is the most common solid tumor outside the brain in children younger than five years old and accounts for about 15% of pediatric cancer deaths.

6 Aug 2026

Long-acting HIV prevention tools could help close the gap before a vaccine arrives

A review of non-vaccine HIV interventions highlights the strong preventive effects of long-acting PrEP, sustained ART, U=U, vertical transmission programs, and voluntary medical male circumcision. Gene editing and multispecific antibodies may expand future options, but safety, cost, access, adherence, and implementation barriers remain.

5 Aug 2026

Targeted dendritic cell vaccines emerge as a major step forward in cancer immunotherapy

A major step forward in cancer immunotherapy is emerging through the growing development of dendritic cell vaccines, a highly targeted approach designed to harness the body's own immune system to fight tumors.

5 Aug 2026

Newly-discovered protein acts as off switch for human immune cells

Mayo Clinic researchers have identified a protein that cancer cells use to shut down the body's immune response, a discovery that could help scientists develop new treatments that make cancer immunotherapies more effective.

3 Aug 2026

Children remain more vulnerable to influenza despite protective antibody levels

Researchers analyzing 1,518 South African household participants found that higher pre-season antibody titers were associated with lower infection risk for three of four influenza viruses studied. Children remained more susceptible after accounting for measured exposure and antibody titers, while younger children shed viral RNA longer than older adults.

3 Aug 2026

New cancer vaccine harnesses COVID-19 immune memory to fight tumors

In a discovery that could redefine the future of cancer immunotherapy, scientists from Celloram Inc., University Hospitals and Case Western Reserve University have developed a novel cancer vaccine platform that transforms the impact of the largest immunological event in modern history – a synchronized mass immune memory generated through SARS-CoV-2 infection and vaccination – into a powerful ally against cancer.

27 Jul 2026